Evidence map›Paper›PMID 33796907›Full record

ArticlePsychopharmacology2021

Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers.

R Ross MacLean, Elise E DeVito, Tore Eid, Suprit Parida, Ralitza Gueorguieva, Mehmet Sofuoglu

Open access · greenAbstract read
In one paragraph

Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

R Ross MacLeanDepartment of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA.
Elise E DeVitoDepartment of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA.
Tore EidDepartment of Laboratory Medicine, School of Medicine, Yale University, New Haven, CT, USA.
Suprit ParidaDepartment of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA.
Ralitza GueorguievaDepartment of Biostatistics, Yale University School of Public Health and School of Medicine, New Haven, CT, USA.
Mehmet SofuogluDepartment of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA. Mehmet.Sofuoglu@yale.edu.
Yale University · USVA Connecticut Healthcare System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Nicotine Reinforcement and Aversion in Young Adult Light SmokersR01DA042528 · NIDA · YALE UNIVERSITY · PI SOFUOGLU, MEHMET · 2016 to 2018
$1.6M
NCATS NIH HHS UL1 TR001863NIDA NIH HHS DA-42528NIDA NIH HHS R01 DA042528
6 · The paper itself

Abstract

rationaleReducing nicotine content of inhaled tobacco products may prevent nicotine addiction, but the threshold for nicotine reinforcement has not been systematically evaluated in controlled human laboratory studies.

objectivesThe current study uses a novel double-blind placebo-controlled intravenous (IV) nicotine self-administration (NSA) model to determine threshold for subjective effects of nicotine and nicotine reinforcement using a forced choice self-administration procedure.

methodsYoung adults (n = 34) had 5 laboratory sessions after overnight nicotine abstinence. In each session, participants sampled and rated the subjective effects of an IV dose of nicotine (0.0125, 0.025, 0.05, 0.1, or 0.2 mg nicotine/70 kg bodyweight) versus saline (placebo), then were given a total of 10 opportunities to self-administer either the IV dose of nicotine or placebo.

resultsMixed effect models revealed a significant effect of nicotine dose for positive (i.e., "stimulatory" and "pleasurable"; p < .0001) effects, but not "aversive" effects during sampling period. Post hoc comparisons showed that higher doses (i.e., 0.1 and 0.2 mg) were associated with greater stimulatory, pleasurable, and physiological effects than placebo and lower doses. Mixed effect models revealed that only the highest dose (i.e., 0.2 mg) was consistently preferred over placebo. Sex differences were generally weak (p = .03-.05).

conclusionsUsing our IV nicotine NSA model, the threshold for detecting positive effects of nicotine in young adult smokers is about 0.1 mg, but a higher dose of nicotine, 0.2 mg, is required to produce a consistent nicotine reinforcement. Regarding the regulatory impact, our findings further support the value of nicotine reinforcement threshold as a tobacco regulatory target.

Indexed as

Reinforcement, PsychologyAdministration, IntravenousAdolescentAdultBlood PressureCigarette SmokingCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHeart RateHumansMaleNicotineNicotinic AgonistsSelf AdministrationNicotineNicotinic AgonistsAbuse liabilityNicotineNicotine reductionSelf-administrationSex

Identifiers

PMID33796907
PMCPMC8715498
OpenAlexW3151631606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.